IRVINE, Calif.--(BUSINESS WIRE)--Oct. 27, 2016--
Masimo
(NASDAQ: MASI), a global innovator of noninvasive patient monitoring
technologies, announced today that Adam Mikkelson, Partner at Camber
Capital Management, LLC, has been elected to Masimo’s Board of Directors.
Mr. Mikkelson has been with Camber Capital Management, a
healthcare-focused investment fund, since 2007. He has almost 15 years
of experience in the healthcare investment arena, focused on identifying
and actively monitoring opportunities in both the therapeutic and
medical device sectors. He received his B.Sc. in Business Administration
from Boston University.
“Adam’s investment experience and deep knowledge of the medical device
industry made him an ideal candidate for Masimo’s Board of Directors,”
said Joe Kiani, Founder, Chairman, and CEO of Masimo. “His insight into
our complex health care system and his standing in the investment
community will be invaluable.”
“I’m excited to be joining Masimo’s Board,” said Mr. Mikkelson. “As a
healthcare investor, I’ve enjoyed watching Masimo grow over the years
via the continued adoption of its innovative monitoring technologies. I
hope that I can make positive contributions to an already strong Board
to drive long-term value for Masimo and its shareholders.”
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027005044/en/
Source: Masimo
Investor Contact:
Masimo
Eli Kammerman
949-297-7077
ekammerman@masimo.com
or
Media
Contact:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com